Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Cp (NQ: ABUS )

2.500 -0.030 (-1.19%)
Streaming Delayed Price Updated: 12:48 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 345,975
Open 2.530
Bid (Size) 2.500 (6)
Ask (Size) 2.510 (27)
Prev. Close 2.530
Today's Range 2.460 - 2.540
52wk Range 1.930 - 6.500
Shares Outstanding 99,161,234
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Arbutus Biopharma Q2 Earnings
  Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-37.19%
-37.19%
1 Month
+2.04%
+2.04%
3 Month
+10.62%
+10.62%
6 Month
-16.39%
-16.39%
1 Year
-12.59%
-12.59%

More News

Read More
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Via Benzinga
Arbutus Biopharma: Q1 Earnings Insights
Via Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
Via Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
Via Investor's Business Daily
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 9
Via Benzinga
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
Via Benzinga
Arbutus Biopharma Earnings Perspective: Return On Capital Employed
Via Benzinga
Arbutus Biopharma: Q4 Earnings Insights
Via Benzinga
Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Via Benzinga
Earnings Scheduled For March 3, 2022
Via Benzinga
Futures, Global Markets Soar In Biggest 4-Day Rally Since November 2020
Via Talk Markets
23 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
Via Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Via Talk Markets
25 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
Via Talk Markets
How Will Moderna Stock Weather Omicron? — And Other Questions Clouding 2022
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.